Skip to Main Content

Author Details

Torsten Haferlach
Taussig Cancer Institute, Cleveland Clinic
1983
660
102
Trey Ideker (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
37994105Massive parallel sequencing unveils homologous recombination deficiency in follicular dendritic cell sarcoma.Haematologica2024
38064663Comparing malignant monocytosis across the updated WHO and ICC classifications of 2022.Blood2024
36253429Molecular landscape of immune pressure and escape in aplastic anemia.Leukemia2023
37634012Genomics of deletion 7 and 7q in myeloid neoplasm: from pathogenic culprits to potential synthetic lethal therapeutic targets.Leukemia2023
37794021TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression.Nat Commun2023
37653344Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma.Nat Med2023
37577681Interface-guided phenotyping of coding variants in the transcription factor RUNX1 with SEUSS.bioRxiv2023
37874914The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing.Blood Adv2023
37573403Risk assessment according to IPSS-M is superior to AML ELN risk classification in MDS/AML overlap patients defined by ICC.Leukemia2023
37537667Novel scheme for defining the clinical implications of TP53 mutations in myeloid neoplasia.J Hematol Oncol2023
37193700Correction: Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.Blood Cancer J2023
37090662The E592K variant of SF3B1 creates unique RNA missplicing and associates with high-risk MDS without ring sideroblasts.Res Sq2023
37088806Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics.Blood Cancer J2023
37390377Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology.JCO Clin Cancer Inform2023
37454239Myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions: reevaluation of the defining characteristics in a registry-based cohort.Leukemia2023
37253784Molecular patterns identify distinct subclasses of myeloid neoplasia.Nat Commun2023
36945617Novel Scheme for Defining the Clinical Implications of TP53 Mutations in Myeloid Neoplasia.Res Sq2023
37474506Computational analysis of peripheral blood smears detects disease-associated cytomorphologies.Nat Commun2023
36926651A multimodal analysis of genomic and RNA splicing features in myeloid malignancies.iScience2023
36789775Prevalence and Therapeutic Implications of Clonal Hematopoiesis of Indeterminate Potential in Young Patients With Stroke.Stroke2023
36480300Biallelic TET2 mutations confer sensitivity to 5'-azacitidine in acute myeloid leukemia.JCI Insight2023
36921004Explainable AI identifies diagnostic cells of genetic AML subtypes.PLOS Digit Health2023
36813994MDS subclassification-do we still have to count blasts?Leukemia2023
36437356Prognostic implications of mono-hit and multi-hit TP53 alterations in patients with acute myeloid leukemia and higher risk myelodysplastic syndromes treated with azacitidine-based therapy.Leukemia2023
36508705Overlapping features of therapy-related and de novo NPM1-mutated AML.Blood2023
36463343Mutations in spliceosome genes in myelodysplastic neoplasms and their association to ring sideroblasts.Leukemia2023
36737231Challenging gold standard hematology diagnostics through the introduction of whole genome sequencing and artificial intelligence.Int J Lab Hematol2023
36930857Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.J Clin Oncol2023
36526738Correction: How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing.Leukemia2023
36823397Novel causative variants of VEXAS in UBA1 detected through whole genome transcriptome sequencing in a large cohort of hematological malignancies.Leukemia2023
36335263How T-lymphoblastic leukemia can be classified based on genetics using standard diagnostic techniques enhanced by whole genome sequencing.Leukemia2023
36241586Artificial intelligence in hematological diagnostics: Game changer or gadget?Blood Rev2023
35989345Precision Medicine in Therapy of Non-solid Cancer.Handb Exp Pharmacol2023
33171257Next-generation diagnostics for precision oncology: Preanalytical considerations, technical challenges, and available technologies.Semin Cancer Biol2022
35617825Pathophysiologic and clinical implications of molecular profiles resultant from deletion 5q.EBioMedicine2022
35732831The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.Leukemia2022
35794096Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age.Nat Commun2022
35761024Rare germline alterations of myeloperoxidase predispose to myeloid neoplasms.Leukemia2022
35725772AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics.Leukemia2022
35519003The Nuclear Proteins TP73 and CUL4A Confer Resistance to Cytarabine by Induction of Translesion DNA Synthesis via Mono-ubiquitination of PCNA.Hemasphere2022
35513723CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk.Nat Genet2022
36480778Implementation of Whole-Genome and Transcriptome Sequencing Into Clinical Cancer Care.JCO Precis Oncol2022
35941213Alternatively spliced CSF3R isoforms in SRSF2 P95H mutated myeloid neoplasms.Leukemia2022
36311800Increased prevalence of clonal hematopoiesis of indeterminate potential in hospitalized patients with COVID-19.Front Immunol2022
36310757Different Gene Sets Are Associated With Azacitidine Response In Vitro Versus in Myelodysplastic Syndrome Patients.Hemasphere2022
36271152SF3B1 mutations in AML are strongly associated with MECOM rearrangements and may be indicative of an MDS pre-phase.Leukemia2022
36169893Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation.Mol Biol Rep2022
36130297Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.Blood2022
36266327Significance of hereditary gene alterations for the pathogenesis of adult bone marrow failure versus myeloid neoplasia.Leukemia2022
36354555A Bioinformatics View on Acute Myeloid Leukemia Surface Molecules by Combined Bayesian and ABC Analysis.Bioengineering (Basel)2022
  • 1 - 50 of 660

Recommended Authors

Matthieu Duchmann
Assistance Publique-Hopitaux de Paris, Universite de Paris
Career Start Year 2015
Number of shared co-authors 8
Panagiotis Baliakas
Uppsala University
Career Start Year 2012
Number of shared co-authors 13
Anna Raimbault
CHU La Miletrie University Hospital Poitiers France.
Career Start Year 2012
Number of shared co-authors 14
Ann-Kathrin Eisfeld
The Ohio State University Comprehensive Cancer Center
Career Start Year 2011
Number of shared co-authors 9
Xinjie Xu
Mayo Clinic
Career Start Year 2011
Number of shared co-authors 5
Il??ana Antony-Debr??
INSERM, France Villejuif Universite Paris-Saclay
Career Start Year 2011
Number of shared co-authors 7
Jennifer Dunlap
Oregon Health & Science University
Career Start Year 2008
Number of shared co-authors 6
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 3
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 2
Don??t Alp??r
Semmelweis University
Career Start Year 2006
Number of shared co-authors 7
Jamshid S Khorashad
Institute of Cancer Research
Career Start Year 2006
Number of shared co-authors 9
Emmanuelle Clappier
Saint-Louis Hospital
Career Start Year 2005
Number of shared co-authors 17
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 19
Naseema Gangat
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 16
Michelle O'Laughlin
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 2003
Number of shared co-authors 4
Sharon E Heath
Washington University School of Medicine.
Career Start Year 2003
Number of shared co-authors 7
Fei Yang
Oregon Health & Science University
Career Start Year 2002
Number of shared co-authors 4
Guang Fan
Oregon Health and Science University
Career Start Year 2000
Number of shared co-authors 4
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 6
Markus Metzler
University Hospital Erlangen
Career Start Year 1998
Number of shared co-authors 10
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 22
Bruno C Medeiros
AbbVie Inc.
Career Start Year 1996
Number of shared co-authors 26
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 20
Mar??a D Odero
University of Navarra
Career Start Year 1994
Number of shared co-authors 2
Derek L Stirewalt
Fred Hutchinson Cancer Center
Career Start Year 1992
Number of shared co-authors 13
Michael Dworzak
St. Anna Children's Cancer Research Institute (CCRI)
Career Start Year 1990
Number of shared co-authors 18
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 9
Jerald P Radich
Fred Hutchinson Cancer Center
Career Start Year 1989
Number of shared co-authors 45
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 11
Krzysztof Mr??zek
The Ohio State Comprehensive Cancer Center
Career Start Year 1988
Number of shared co-authors 29

Collaborators

Alexander Kohlmann
Oncology R&D
Co-authored papers 107
Seishi Ogawa
Kyoto University
Co-authored papers 23
Stefan Hutter
University Hospital
Co-authored papers 21
Wolfgang E Berdel
University Hospital Munster
Co-authored papers 17
Hans-Ulrich Klein
Columbia University Irving Medical Center
Co-authored papers 16
Satoru Miyano
Tokyo Medical and Dental University
Co-authored papers 13
Michael Heuser
Hannover Medical School
Co-authored papers 11
Charles G Mullighan
St Jude Children's Research Hospital
Co-authored papers 9
Luca Malcovati
University of Pavia & S. Matteo Hospital
Co-authored papers 9
Hiroko Tanaka
Tokyo Medical and Dental University
Co-authored papers 9
Robin Fo??
Sapienza University.
Co-authored papers 9
Felicitas Thol
Hannover Medical School
Co-authored papers 8
Henry Yang
Cancer Science Institute of Singapore, National University of Singapore
Co-authored papers 7
Steven M Kornblau
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Hagop Kantarjian
The University of Texas MD Anderson Cancer Center
Co-authored papers 7
Joop H Jansen
Co-authored papers 7
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Co-authored papers 6
Benjamin L Ebert
Co-authored papers 6
Thomas LaFramboise
Co-authored papers 6
Robert Kralovics
Medical University of Vienna
Co-authored papers 6
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 6
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Co-authored papers 5
Olivier Elemento
Meyer Cancer Center
Co-authored papers 5
Thomas Ernst
Universitatsklinikum Jena
Co-authored papers 5
Claude Preudhomme
Lille University Hospital, INSERM UMR-S7, CNRS UMR9020, Lille University.
Co-authored papers 5
Sean M Grimmond
The University of Melbourne
Co-authored papers 5
Carlos Caldas
Cancer Research UK Cambridge Institute, University of Cambridge
Co-authored papers 4
Bert A van der Reijden
Co-authored papers 4
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Co-authored papers 4
Stephan Hutter
Fondazione IRCCS Policlinico San Matteo, University of Pavia
Co-authored papers 4
Release 1.2